Salvage therapy for relapsed/refractory diffuse large B cell lymphoma

被引：34

作者：

Sesbadri, Tara ^{[1
]}

Kuruvilla, Fohn ^{[1
]}

Crump, Michael ^{[1
]}

Keating, Armand ^{[1
]}

机构：

[1] Princess Margaret Hosp, Autologous Blood & Marrow Transplant Program, Toronto, ON M5G 2M9, Canada

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2008年 / 14卷 / 03期

关键词：

diffuse large B cell lymphoma; relapsed; refractory; salvage therapy;

D O I：

10.1016/j.bbmt.2007.11.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diffuse large B cell lymphoma (DLBCL), the most common subtype of aggressive lymphoma, has considerable biologic and clinical heterogeneity. Despite recent therapeutic advances, up to 50% of patients relapse after standard chemoimmunotherapy. The International Prognostic Index (IPI) at relapse is of value in providing prognostic information on response to salvage chemotherapy and outcome after autologous hematopoietic cell transplantation (aHCT). Predictive biologic and gene expression markers, however, remain undefined, and require further clarification from additional molecular studies. To date, the standard of care in the management of relapsed/refractory DLBCL is salvage chemotherapy followed by an aHCT for those with chemotherapy-sensitive disease. Currently, there is no standard salvage chemotherapy regimen, and the use of immunotherapy for relapsed disease requires further evaluation. This review focuses on prognostic markers, current salvage therapies, and discusses the role of novel treatment in the management of relapsed/refractory DLBCL. (C) 2008 American Society for Blood and Marrow Transplantation.

引用

页码：259 / 267

页数：9

共 75 条

[1] Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach [J].

Abramson, JS ;

Shipp, MA .

BLOOD, 2005, 106 (04) :1164-1174

[2] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[3] Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma [J].

Andreadis, Charalambos ;

Gimotty, Phyllis A. ;

Wahl, Peter ;

Hammond, Rachel ;

Houldsworth, Jane ;

Schuster, Stephen J. ;

Rebbeck, Timothy R. .

BLOOD, 2007, 109 (08) :3409-3416

[4]

ANTMAN KH, 1985, CANCER TREAT REP, V69, P499

[5] Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens [J].

Ardeshna, KM ;

Kakouros, N ;

Qian, W ;

Powell, MG ;

Saini, N ;

D'Sa, S ;

Mackinnon, S ;

Hoskin, PJ ;

Goldstone, AH ;

Linch, DC .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) :363-372

[6] Gemcitabine and cisplatin in refractory malignant lymphoma [J].

Avilés, A ;

Neri, N ;

Huerta-Guzmán, J ;

Fernández, R .

ONCOLOGY, 2004, 66 (03) :197-200

[7] A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma [J].

Biagi, JJ ;

Herbert, KE ;

Smith, C ;

Abdi, E ;

Leahy, M ;

Falkson, C ;

Wolf, M ;

Januszewicz, H ;

Seymour, JF ;

Richards, K ;

Matthews, JP ;

Dale, B ;

Prince, HM .

LEUKEMIA & LYMPHOMA, 2005, 46 (02) :197-206

[8]

Blay JY, 1998, BLOOD, V92, P3562

[9] 'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions' [J].

Bonavida, B. .

ONCOGENE, 2007, 26 (25) :3629-3636

[10] An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma [J].

Chau, I ;

Webb, A ;

Cunningham, D ;

Hill, M ;

Rao, S ;

Ageli, S ;

Norman, A ;

Gill, K ;

Howard, A ;

Catovsky, D .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :786-792

← 1 2 3 4 5 6 7 8 →